The management team of PharOS discuss the company’s move from generics consultancy to co-developer, surviving in the Greek market, and internationalization plans.
Founded back in 2002, PharOS has gained a formidable reputation as a pharma development company for bringing best in class generics products to market and prolonging their life span. Could you please start by introducing the company and the main milestones in PharOS’ evolution?
"[We are] a privately owned company developing generics and value added pharmaceuticals with a global portfolio of over 50 products and over 5,000 marketing authorizations worldwide."
